Gastrointestinal Drugs Advisory Committee Roster

OTC Monograph Drug User Fee Program (OMUFA); Understanding FY 2025 User Fees and Registration

Sponsor Responsibilities – Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies

The Food and Drug Administration is advising consumers not to purchase or use Rhino Gummy Royal 50000, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.

Information related to FDA’s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.

FDA encourages the early adoption of advanced manufacturing technologies (AMTs) that have the potential to benefit patients by improving manufacturing and supply dependability and optimizing development time of drug and biological products.

Innovative drugs often mean new treatment options for patients and advances in health care for the American public.